Clinical Trials Browser

Phase 1 × Myelodysplastic Syndromes × tandutinib × Clear all

NCT00064584 2009-03-24

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute